An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.

Jing XuYi GaoXiaotian LuanKe LiJing WangYilin DaiMingyi KangChong LuMinhua ZhangChris X LuYu KangCongjian Xu

Published in: Cancer chemotherapy and pharmacology (2022)

Collectively, our results suggest that the combination of AKT inhibitor and PARP inhibitor could be a viable approach for clinical testing in recurrent ovarian cancer patients.

Keyphrases

combination therapy
signaling pathway
cell proliferation
oxidative stress